EUCTR2010-021651-79-IT进行中（未招募）1 期
Studio degli effetti immuno-virologici dell’interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 个研究点目标入组 30 人开始时间: 2012年4月13日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •age > 18 years •HIV infected, antiretroviral experienced patients •Stable HAART regimen containing maraviroc for at least 6 months •Confirmed (two consecutive determinations) HIV-1 RNA>50 copies/ml •Genotypic Sensitivity Score < equal to 1 (Patients without the possibility of constructing an effective HAART as recommended by guidelines)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnancy and breast feeding women • Immediate availability of an effective HAART • Acute illness that in the opinion of the investigator might be aggravated by a partial interruption of antiretroviral treatment.
研究者
相似试验
已完成
2 期
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315HIV InfectionsNCT00000891National Institute of Allergy and Infectious Diseases (NIAID)34
进行中（未招募）
不适用
Immunological and virological effects of high dose intravenous immunoglobulin (IVIG) treatment added to antiretroviral therapy against HIVEUCTR2005-003422-26-SEGöteborg University5
尚未招募
1 期
Safety and Immunological Response following Intradermal COVID-19 vaccination in The Booster (3rd dose)healthy volunteerImmunizationCOVID-19 VaccineIntradermalBooster3rd doseTCTR20211102006Faculty of Medicine Siriraj Hospital, Mahidol University105
进行中（未招募）
1 期
Evaluación de los cambios inmunológicos tras la inmunoterapia subcutánea con un extracto de Phleum pratenseRhinoconjunctivitisMedDRA version: 7.1Level: PTClassification code 10010744EUCTR2005-003460-35-ESALK-Abelló, S.A.
已完成
不适用
Evaluation of Immunological Changes in patients treated with CyberKnife® radiosurgery and RadiotherapyCTRI/2011/06/001800Health Care Global Enterprises Ltd100